W H Choi1, I R Yoo, J H O, S H Kim, S K Chung. 1. Department of Radiology, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
Abstract
OBJECTIVE: The sensitivity of 18-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) for detecting axillary lymph node (ALN) metastases in breast cancer is reported to be low. Several studies have shown, however, that dual-time-point (18)F-FDG PET imaging provides improved accuracy in the diagnosis of certain primary tumours when compared with single-scan imaging. The purpose of this study was to assess whether the use of dual-time-point (18)F-FDG PET/CT scans could improve the diagnostic accuracy of ALN metastasis in breast cancer. METHOD: The study included 171 breast cancer patients who underwent pre-operative (18)F-FDG PET/CT scans at 2 time-points, the first at 1 h after radiotracer injection and the second 3 h after injection. Where (18)F-FDG uptake was in the ALN perceptibly increased, the maximum standardised uptake values for both time-points (SUVmax1 and SUVmax2) and the retention index (RI) were calculated. Correlation between the PET/CT results and post-operative histological results was assessed. RESULTS: The performance of 1 h and 3 h PET/CT scans was equal, with sensitivity 60.3% and specificity 84.7%, in detecting ALN metastasis. Out of 171 patients, 60 had ALNs with increased (18)F-FDG uptake on 1 h or 3 h images. There was no significant difference in RI between the metastatic ALN-positive group and the node-negative group. The area under the receiver operating characteristic (ROC) curve for SUVmax1 was 0.90 (p<0.001) and 0.87 for SUVmax2 (p<0.001). CONCLUSION: Dual time-point imaging did not improve the overall performance of (18)F-FDG PET/CT in detecting ALN metastasis in breast cancer patients.
OBJECTIVE: The sensitivity of 18-fluorodeoxyglucose ((18)F-FDG) positron emission tomography (PET) for detecting axillary lymph node (ALN) metastases in breast cancer is reported to be low. Several studies have shown, however, that dual-time-point (18)F-FDG PET imaging provides improved accuracy in the diagnosis of certain primary tumours when compared with single-scan imaging. The purpose of this study was to assess whether the use of dual-time-point (18)F-FDG PET/CT scans could improve the diagnostic accuracy of ALN metastasis in breast cancer. METHOD: The study included 171 breast cancerpatients who underwent pre-operative (18)F-FDG PET/CT scans at 2 time-points, the first at 1 h after radiotracer injection and the second 3 h after injection. Where (18)F-FDG uptake was in the ALN perceptibly increased, the maximum standardised uptake values for both time-points (SUVmax1 and SUVmax2) and the retention index (RI) were calculated. Correlation between the PET/CT results and post-operative histological results was assessed. RESULTS: The performance of 1 h and 3 h PET/CT scans was equal, with sensitivity 60.3% and specificity 84.7%, in detecting ALN metastasis. Out of 171 patients, 60 had ALNs with increased (18)F-FDG uptake on 1 h or 3 h images. There was no significant difference in RI between the metastatic ALN-positive group and the node-negative group. The area under the receiver operating characteristic (ROC) curve for SUVmax1 was 0.90 (p<0.001) and 0.87 for SUVmax2 (p<0.001). CONCLUSION: Dual time-point imaging did not improve the overall performance of (18)F-FDG PET/CT in detecting ALN metastasis in breast cancerpatients.
Authors: Jacobus J M van der Hoeven; Otto S Hoekstra; Emile F I Comans; Rik Pijpers; Robert P A Boom; Dick van Geldere; Sybren Meijer; Adriaan A Lammertsma; Gerrit J J Teule Journal: Ann Surg Date: 2002-11 Impact factor: 12.969
Authors: Ulrich Guller; Egbert U Nitzsche; Udo Schirp; Carsten T Viehl; Joachim Torhorst; Holger Moch; Igor Langer; Walter R Marti; Daniel Oertli; Felix Harder; Markus Zuber Journal: Breast Cancer Res Treat Date: 2002-01 Impact factor: 4.872
Authors: Winkle Kwan; Jeremy Jackson; Lorna M Weir; Carol Dingee; Greg McGregor; Ivo A Olivotto Journal: J Clin Oncol Date: 2002-10-15 Impact factor: 44.544
Authors: H Zhuang; M Pourdehnad; E S Lambright; A J Yamamoto; M Lanuti; P Li; P D Mozley; M D Rossman; S M Albelda; A Alavi Journal: J Nucl Med Date: 2001-09 Impact factor: 10.057
Authors: Scott D Wollenweber; Gaspar Delso; Timothy Deller; David Goldhaber; Martin Hüllner; Patrick Veit-Haibach Journal: MAGMA Date: 2013-06-26 Impact factor: 2.310
Authors: Stephen P Povoski; Douglas A Murrey; Sabrina M Smith; Edward W Martin; Nathan C Hall Journal: BMC Cancer Date: 2014-06-19 Impact factor: 4.430